<DOC>
	<DOCNO>NCT01833130</DOCNO>
	<brief_summary>This study evaluate use Assessment Chronic Migraine Impacts ( ACM-I ) Questionnaire assess impact benefit treatment onabotulinumtoxinA ( BOTOX® ) adults chronic migraine .</brief_summary>
	<brief_title>Use Treatment Benefit Questionnaire Patients With Chronic Migraine Treated With OnabotulinumtoxinA ( BOTOX® )</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>History chronic migraine least 6 month prior screen visit Fifteen headache day 4week screening period ( ≥4 headache episode last ≥4 hour ≥50 % headache day migraine ) Conditions cause chronic facial pain Temporomandibular Disorder ( TMD ) fibromyalgia Use headache prophylaxis medication within 4 week screen visit Diagnosis Myasthenia gravis , EatonLambert Syndrome , Amyotrophic Lateral Sclerosis Previous use botulinum toxin serotype reason Skin infection acne would interfere injection site Acupuncture , transcutaneous electrical nerve stimulation ( TENS ) , cranial traction , dental splint headache , nociceptive trigeminal inhibition , occipital nerve block treatment , injection anesthetics/steroids within 4 week screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>